Description: Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Home Page: www.zymeworks.com
ZYME Technical Analysis
114 East 4th Avenue
Vancouver,
BC
V5T 1G4
Canada
Phone:
604-678-1388
Officers
| Name | Title |
|---|---|
| Mr. Neil A. Klompas C.A., CPA, CA, CPA | Pres & COO |
| Dr. Ali Tehrani Ph.D. | Advisor |
| Dr. Neil Josephson M.D. | Chief Medical Officer |
| Mr. Kenneth H. Galbraith C.A. | CEO & Chairman |
| Dr. Christopher Astle Ph.D. | Sr. VP & CFO |
| Dr. Paul Moore Ph.D. | Chief Scientific Officer |
| Jack W. Spinks | Mang. of Investor Relations |
| Mr. Daniel Dex J.D., Ph.D. | VP of Legal & Corp. Sec. |
| Mr. Mark Hollywood | Sr. VP of Technical & Manufacturing Operations |
| Dr. David Poon Ph.D. | VP of Bus. Devel. and Alliance Management |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7819 |
| Price-to-Sales TTM: | 13.3063 |
| IPO Date: | 2017-04-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 286 |